ALUMIS INC.
ALMSDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ALMS Earnings Report
EPS Est: $-0.70 | FQ end 2026-06
How ALMS's past catalysts played out
Open-Label ESK-001
Plaque Psoriasis
ESK-001
Plaque Psoriasis
Apremilast
Plaque Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Open-Label ESK-001 | Phase 3 | Plaque Psoriasis | - | - |
ESK-001 | Phase 3 | Plaque Psoriasis | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ALUMIS INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in ALUMIS INC.'s (ALMS) pipeline across Phase 3. Its lead program is Open-Label ESK-001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ALUMIS INC.'s next FDA catalyst?→
ALUMIS INC.'s (ALMS) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALMS biotech catalysts?→
Add ALMS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ALUMIS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.